Fracture Liaison Services: Reimbursement Mechanics and Operator Economics | Policy & Market Intelligence

Description

List of Tables

In April 2022 Japan's NHI system began paying for fracture liaison services, and with that one fee-schedule change, secondary fracture prevention acquired a business model. The logic of an FLS is simple: a coordinator identifies fragility-fracture patients inside the hospital, ensures they are assessed for osteoporosis, initiates or arranges treatment, and follows them so therapy continues. The economics, however, are not simple. The fee schedule defines what can be billed, hospital archetypes differ in staffing, case volume, and cost structure, and whether an FLS runs at a surplus depends on details that are invisible from the outside.

This opacity cuts both ways. Hospital executives considering an FLS cannot easily benchmark staffing models or fee capture against peers. Pharma companies funding patient-support programs cannot easily tell which hospital configurations convert support into sustained treatment. Care-coordination software vendors cannot easily size the segment. And international experience, from the UK's FLS database to the IOF Capture the Fracture accreditation program, translates imperfectly into Japanese fee mechanics. The result is that a policy intervention designed to close the post-fracture treatment gap is itself unevenly adopted, for reasons that are economic and operational rather than clinical.

This report opens the black box. It reconstructs the April 2022 fee schedule line by line: what each component pays for, what documentation it requires, and how billing interacts with existing inpatient and outpatient fees. It then builds hospital archetypes, academic centers, community hospitals with orthopedic volume, and rehabilitation-focused institutions, and models the staffing, workflow, and capture-rate conditions under which each runs an FLS profitably. The report profiles the ecosystem around the service: Amgen, UCB, Lilly, Teijin, Asahi Kasei, Daiichi Sankyo, and Chugai as therapy stakeholders with patient-services programs; M3 and Medley as coordination-software participants; and IOF Capture the Fracture as the international accreditation layer.

The report is written for hospital networks evaluating service-line economics, care-coordination and hospital-software vendors, pharma patient-services and market-access teams, and investors assessing the secondary-prevention segment. Every economic claim is tied to a fee-schedule line or an operating-model assumption that the reader can inspect and adjust.

Scope and Coverage

The report covers FLS reimbursement mechanics, hospital operating models, and ecosystem economics in Japan, with structural comparison to the UK, other EU5 systems, the US, and China. It addresses service design and economics rather than drug-level clinical questions, which are covered in the companion osteoporosis treatment-gap report.

Report Highlights

Line-by-line reconstruction of the April 2022 FLS fee schedule
Hospital archetype models: staffing, workflow, and fee-capture conditions
Break-even and surplus conditions for FLS operation by archetype
Pharma patient-services programs and their interaction with hospital FLS
Coordination-software and documentation vendor landscape
International FLS models: UK FLS-DB and IOF accreditation benchmarks

Product Code: JPH-011

Table of Content

1. Executive Summary

2. Fracture Liaison Services: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

Amgen (US) - Prolia and Evenity with FLS support programs and patient-services funding
UCB (BE) - romosozumab partner and international FLS advocacy
Eli Lilly (US) - Forteo and historical bone-health service programs
Hikma (UK) - teriparatide biosimilar pricing pressure on FLS drug budgets
Teijin (JP) - Ostabalo and Japanese FLS promotion activities
Asahi Kasei (JP) - teriparatide acetate and domestic osteoporosis franchise
Daiichi Sankyo (JP) - bisphosphonate portfolio used in FLS protocols
Chugai (JP) - Edirol within FLS treatment algorithms
M3 (JP) - digital coordination platforms used by hospital programs
Medley (JP) - hospital operations software relevant to FLS documentation
IOF Capture the Fracture (CH) - international FLS accreditation program endorsing Japanese sites

Product Code: JPH-011

List of Tables

Table 1. Fracture liaison service concept: components, staffing, and objectives
Table 2. Secondary-fracture prevention evidence base: program-design literature
Table 3. IOF Capture the Fracture standards and accreditation levels
Table 4. Milestones in Japanese FLS policy by year
Table 5. FLS-eligible patient populations: fracture sites and age bands
Table 6. Hospital case-flow structures relevant to FLS capture
Table 7. Coordinator staffing models: nurses, pharmacists, and administrative hybrids
Table 8. Referral relationships between orthopedic, rehabilitation, and primary-care units
Table 9. Prefectural variation in FLS adoption frameworks
Table 10. April 2022 fee schedule: component inventory and billing definitions
Table 11. FLS management-fee structure: eligibility, documentation, and claim mechanics
Table 12. Interaction of FLS fees with inpatient and outpatient fee schedules
Table 13. Rehabilitation-fee interfaces for post-fracture patients
Table 14. Documentation and registry requirements attached to billing
Table 15. Fee-capture failure modes: operational causes of unbilled components
Table 16. Academic-center FLS archetype: structure, staffing, and economics
Table 17. Community-hospital FLS archetype: orthopedic-volume-dependent model
Table 18. Rehabilitation-hospital FLS archetype: long-stay patient flow model
Table 19. Clinic-linked and network-based FLS variants
Table 20. Coordinator productivity frameworks: case load per coordinator
Table 21. Treatment-initiation and continuation protocols within FLS programs
Table 22. DXA and laboratory assessment workflow inside FLS operations
Table 23. Patient-communication and adherence-support program designs
Table 24. Data-collection and outcomes-reporting infrastructure
Table 25. PMDA and guideline context for therapies initiated through FLS
Table 26. NHI drug-pricing structure for therapies used in FLS protocols
Table 27. Bisphosphonate, denosumab, and anabolic positioning within FLS formularies
Table 28. Biosimilar entry effects on FLS drug budgets
Table 29. Hospital procurement structures for osteoporosis injectables
Table 30. UK FLS Database model: structure and benchmarking approach
Table 31. Other EU5 FLS implementations and funding mechanisms
Table 32. US coordinator-model economics under commercial and Medicare payment
Table 33. China secondary-prevention service status
Table 34. Amgen patient-services programs linked to Prolia and Evenity
Table 35. UCB international FLS advocacy structures
Table 36. Lilly, Teijin, and Asahi Kasei bone-health service programs
Table 37. Daiichi Sankyo and Chugai products within FLS treatment algorithms
Table 38. Hikma and biosimilar pricing pressure on FLS drug budgets
Table 39. M3 digital coordination platforms used by hospital programs
Table 40. Medley hospital-operations software relevant to FLS documentation
Table 41. IOF Capture the Fracture endorsement process for Japanese sites
Table 42. Professional-society support structures for FLS development
Table 43. Unmet needs: hospitals without viable FLS economics under current fees
Table 44. Fee-schedule reform options and their implications
Table 45. Software and workflow opportunities in FLS operations
Table 46. Pharma program-design opportunities aligned to hospital archetypes
Table 47. Network and regional FLS models for low-volume hospitals
Table 48. Decision framework for hospital executives evaluating FLS adoption
Table 49. Report methodology: fee-schedule analysis, archetype modeling, and interview base
Table 50. Glossary of fees, programs, and service terms

List of Figures

Figure 1. FLS operating concept diagram
Figure 2. Secondary-prevention program-design literature map
Figure 3. Capture the Fracture standards framework
Figure 4. Japanese FLS policy timeline
Figure 5. FLS-eligible patient funnel
Figure 6. Hospital case-flow structure relevant to capture
Figure 7. Coordinator staffing model comparison
Figure 8. Inter-unit referral relationship map
Figure 9. Prefectural FLS adoption variation framework
Figure 10. April 2022 fee schedule component map
Figure 11. FLS management-fee claim flow
Figure 12. Fee-schedule interaction diagram
Figure 13. Rehabilitation-fee interface schematic
Figure 14. Documentation and registry requirement flow
Figure 15. Fee-capture failure-mode map
Figure 16. Academic-center archetype operating model
Figure 17. Community-hospital archetype operating model
Figure 18. Rehabilitation-hospital archetype operating model
Figure 19. Clinic-linked and network FLS variant diagram
Figure 20. Coordinator productivity framework schematic
Figure 21. Treatment-initiation and continuation protocol flow
Figure 22. Assessment workflow inside FLS operations
Figure 23. Adherence-support program design map
Figure 24. Data and reporting infrastructure diagram
Figure 25. Therapy regulatory and guideline context map
Figure 26. NHI drug-pricing structure for FLS therapies
Figure 27. Formulary positioning within FLS protocols
Figure 28. Biosimilar entry impact flow on drug budgets
Figure 29. Hospital procurement structure for injectables
Figure 30. UK FLS Database model diagram
Figure 31. EU5 FLS implementation map
Figure 32. US coordinator-model payment structure
Figure 33. China secondary-prevention status map
Figure 34. Amgen patient-services program architecture
Figure 35. UCB advocacy structure diagram
Figure 36. Lilly, Teijin, and Asahi Kasei service-program map
Figure 37. Daiichi Sankyo and Chugai algorithm positions
Figure 38. Biosimilar pricing pressure pathway
Figure 39. M3 coordination platform structure
Figure 40. Medley documentation software map
Figure 41. Capture the Fracture endorsement pathway
Figure 42. Professional-society support structure
Figure 43. Non-viable-hospital map under current fees
Figure 44. Fee-schedule reform option tree
Figure 45. Software and workflow opportunity map
Figure 46. Pharma program-design alignment framework
Figure 47. Regional FLS network model schematic
Figure 48. Hospital executive decision framework
Figure 49. Methodology flow: fees, archetypes, and interviews
Figure 50. Data cut-off and update cadence schematic

Fracture Liaison Services: Reimbursement Mechanics and Operator Economics | Policy & Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Fracture Liaison Services: Policy and Institutional Framework

3. Reimbursement, Pricing, and Funding Flows

4. Provider and Operator Landscape: Structure and Economics

5. Workforce and Capacity Analysis

6. Technology and Vendor Ecosystem

7. International Comparison: US, EU5, and China

8. Implications for Entrants and Investors

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures